Effectively simplified Adriamycin-induced chronic kidney disease mouse model: Retro-orbital vein injection versus tail-vein injection

Abstract

This study aimed to investigate the impact of administration routes in establishing the Adriamycin (ADR)-induced chronic kidney disease (CKD) model. Using BALB/c mice, we compared the effects of conventional tail-vein injection (TV10, 10 mg/kg) to those of retro-orbital sinus (orbital vein) injection (OV10, 10 mg/kg; OV8, 8 mg/kg). The results indicated that the OV10 group exhibited CKD pathology similar to the TV10 group, with both groups demonstrating significantly higher urinary albumin/creatinine ratio (p < 0.05), tubular injury (p < 0.05), and degree of renal fibrosis (p < 0.05) than the OV8 group. No significant differences were observed between the OV10 and TV10 groups in urinary albumin/creatinine ratio, tubular injury, and degree of renal fibrosis. These findings demonstrated that retro-orbital administration of 10 mg/kg ADR induces comparable effects to conventional tail-vein administration. This technique's technical simplicity may improve experimental efficiency, reproducibility, and animal welfare in CKD research. In conclusion, this study validates the utility of retro-orbital injection in CKD model establishment, demonstrating its potential to standardize and improve the reliability of future CKD research protocols.

Keywords

Adriamycin nephropathy / BALB/c / CKD / orbital vein injection / tail-vein injection

References

[1] Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013; 382(9888): 260-272.

[2] Plantinga LC, Boulware LE, Coresh J, et al. Patient awareness of chronic kidney disease: trends and predictors. Arch Intern Med. 2008; 168(20): 2268-2275.

[3] Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS 64). Kidney Int. 2003; 63(1): 225-232.

[4] Köttgen A, Pattaro C, Böger C, et al. New loci associated with kidney function and chronic kidney disease. Nat Genet. 2010; 42(5): 376-384.

[5] Ellis JW, Chen M, Foster MC, et al. Validated SNPs for eGFR and their associations with albuminuria. Hum Mol Genet. 2012; 21(14): 3293-3298.

[6] Fogo AB. Animal models of FSGS: lessons for pathogenesis and treatment. Semin Nephrol. 2003; 23(2): 161-171.

[7] Watanabe M, Takahashi Y, Hiura K, et al. A single amino acid substitution in PRKDC is a determinant of sensitivity to Adriamycin-induced renal injury in mouse. Biochem Biophys Res Commun. 2021; 556: 121-126.

[8] Watanabe M, Hiura K, Sasaki H, Okamura T, Sasaki N. Genetic background strongly influences the transition to chronic kidney disease of adriamycin nephropathy in mice. Exp Anim. 2023; 72(1): 47-54.

[9] Schoch A, Thorey IS, Engert J, Winter G, Emrich T. Comparison of the lateral tail vein and the retro-orbital venous sinus routes of antibody administration in pharmacokinetic studies. Lab Anim. 2014; 43(3): 95-99.

[10] Price JE, Barth RF, Johnson CW, Staubus AE. Injection of cells and monoclonal antibodies into mice: comparison of tail vein and retroorbital routes. Proc Soc Exp Biol Med. 1984; 177(2): 347-353.

[11] Steel CD, Stephens AL, Hahto SM, Singletary SJ, Ciavarra RP. Comparison of the lateral tail vein and the retro-orbital venous sinus as routes of intravenous drug delivery in a transgenic mouse model. Lab Anim. 2008; 37(1): 26-32.

[12] Yardeni T, Eckhaus M, Morris HD, Huizing M, Hoogstraten-Miller S. Retro-orbital injections in mice. Lab Anim. 2011; 40(5): 155-160.

[13] Papeta N, Zheng Z, Schon EA, et al. Prkdc participates in mitochondrial genome maintenance and prevents Adriamycin-induced nephropathy in mice. J Clin Invest. 2010; 120(11): 4055-4064.

[14] Watanabe M, Ishii Y, Hashimoto K, Takimoto HR, Sasaki N. Development and characterization of a novel FVB-Prkdc(R2140C) mouse model for adriamycin-induced nephropathy. Genes (Basel). 2024; 15(4): 456.

[15] Tampe D, Schridde L, Korsten P, et al. Different patterns of kidney fibrosis are indicative of injury to distinct renal compartments. Cells. 2021; 10(8): 2014.

[16] Huang R, Fu P, Ma L. Kidney fibrosis: from mechanisms to therapeutic medicines. Signal Transduct Target Ther. 2023; 8(1): 129.

[17] Bohle A, Müller GA, Wehrmann M, Mackensen-Haen S, Xiao JC. Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies, and chronic interstitial nephritides. Kidney Int. 1996; 54: 2.

[18] Takahashi Y, Watanabe M, Hiura K, Isobe A, Sasaki H, Sasaki N. Positive correlation between renal tubular flattening and renal tubular injury/interstitial fibrosis in murine kidney disease models. J Vet Med Sci. 2021; 83(3): 397-402.

[19] GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017; 390(10100): 1151-1210.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.